Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?
Erlend SkagaMarthe Andrea SkrettebergTom Børge JohannesenPetter BrandalEinar O Vik-MoEirik HelsethIver A LangmoenPublished in: Neuro-oncology advances (2021)
Patients considered eligible for phase III clinical trials represent a highly selected minority of patients in a real-world GBM population.